<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">25920920</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>09</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1460-2385</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>31</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</Title>
          <ISOAbbreviation>Nephrol Dial Transplant</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lupus nephritis management guidelines compared.</ArticleTitle>
        <Pagination>
          <StartPage>904</StartPage>
          <EndPage>913</EndPage>
          <MedlinePgn>904-13</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/ndt/gfv102</ELocationID>
        <Abstract>
          <AbstractText>In the past years, many (randomized) trials have been performed comparing the treatment strategies for lupus nephritis. In 2012, these data were incorporated in six different guidelines for treating lupus nephritis. These guidelines are European, American and internationally based, with one separate guideline for children. They offer information on different aspects of the management of lupus nephritis including induction and maintenance treatment of the different histological classes, adjunctive treatment, monitoring of the patient, definitions of response and relapse, indications for (repeat) renal biopsy, and additional challenges such as the presence of vascular complications, the pregnant SLE patient, treatment in children and adolescents and considerations about end-stage renal disease and transplantation. In this review, we summarize the guidelines, determine the common ground between them, highlight the differences and discuss recent literature.</AbstractText>
          <CopyrightInformation>Â© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wilhelmus</LastName>
            <ForeName>Suzanne</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bajema</LastName>
            <ForeName>Ingeborg M</ForeName>
            <Initials>IM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bertsias</LastName>
            <ForeName>George K</ForeName>
            <Initials>GK</Initials>
            <AffiliationInfo>
              <Affiliation>Rheumatology, Clinical Immunology and Allergy, Medical School, University of Crete, Iraklion, Greece Infections and Immunity Division, IMBB-FORTH, Iraklion, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boumpas</LastName>
            <ForeName>Dimitrios T</ForeName>
            <Initials>DT</Initials>
            <AffiliationInfo>
              <Affiliation>Infections and Immunity Division, IMBB-FORTH, Iraklion, Greece Biomedical Research Foundation of the Academy of Athens, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gordon</LastName>
            <ForeName>Caroline</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, The Medical School, University of Birmingham, Birmingham, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lightstone</LastName>
            <ForeName>Liz</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Renal Medicine and Vascular Inflammation, Department of Medicine, Imperial College London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tesar</LastName>
            <ForeName>Vladimir</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, 1st School of Medicine, Charles University, Prague, Czech Republic.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jayne</LastName>
            <ForeName>David R</ForeName>
            <Initials>DR</Initials>
            <AffiliationInfo>
              <Affiliation>Addenbrooke's Hospital, Lupus and Vasculitis Unit, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>20108</GrantID>
            <Acronym>ARC_</Acronym>
            <Agency>Arthritis Research UK</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>20108</GrantID>
            <Acronym>VAC_</Acronym>
            <Agency>Versus Arthritis</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>04</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nephrol Dial Transplant</MedlineTA>
        <NlmUniqueID>8706402</NlmUniqueID>
        <ISSNLinking>0931-0509</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007676" MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008181" MajorTopicYN="N">Lupus Nephritis</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName>
          <QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">guideline</Keyword>
        <Keyword MajorTopicYN="Y">lupus nephritis</Keyword>
        <Keyword MajorTopicYN="Y">management</Keyword>
        <Keyword MajorTopicYN="Y">systemic lupus erythematosus</Keyword>
        <Keyword MajorTopicYN="Y">treatment</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2014</Year>
          <Month>11</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25920920</ArticleId>
        <ArticleId IdType="doi">10.1093/ndt/gfv102</ArticleId>
        <ArticleId IdType="pii">gfv102</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
